Xilio Therapeutics, Inc.
XLOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 21, 2026 | Raymond James | Sean McCutcheon | $16.00(+87%) | $8.54 | StreetInsider |
| Dec 21, 2022 | Chardan Capital | $7.00(-75%) | $27.58 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Raymond James | maintain | Outperform | Nov 8, 2024 |
| Chardan Capital | maintain | Buy | May 30, 2023 |
| Morgan Stanley | maintain | Overweight | Jan 27, 2023 |
| Raymond James | maintain | Outperform | Nov 10, 2022 |
| Morgan Stanley | maintain | Overweight | Aug 10, 2022 |
Earnings History
Next report: Mar 3, 2027 · EPS est. $-0.97| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.33 | $-0.59 | $18.7M | $12.7M |
| May 12, 2026 | $-0.58 | $-0.66 | $12.7M | $8.5M |
| Mar 23, 2026 | $-0.85 | $-1.68 | $13.7M | $10.9M |
| Nov 13, 2025 | $-1.54 | $-0.42 | $19.1M | $18.6M |
| Aug 14, 2025 | $-2.24 | $-1.12 | $8.1M | $8.2M |
| May 8, 2025 | $-2.52 | $-0.11 | $2.9M | $4.4M |
| Mar 11, 2025 | $-2.80 | $-3.08 | $1.7M | $3.3M |
| Nov 7, 2024 | $-3.08 | $-3.50 | $2.3M | $3.3M |
News
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will present at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026 at 2:40 p.m. ET.
XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumors
WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics' Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022…
Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncology Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncology
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1; IND applications anticipated in the second half of 2027 Cash runway into the first quarter of 2028 expected to support key milestones across pipeline of next generation multi-specific I-O therapies WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) --…